123 related articles for article (PubMed ID: 6495691)
1. [Use of tamoxifen in patients with disseminated and local breast neoplasms].
Semiglazov VF; Gershanovich ML; Kondrat'ev VB; Moiseenko VM
Vopr Onkol; 1984; 30(9):39-43. PubMed ID: 6495691
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer.
Beex L; Pieters G; Smals A; Koenders A; Benraad T; Kloppenborg P
Cancer Treat Rep; 1981; 65(3-4):179-85. PubMed ID: 7237448
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
[TBL] [Abstract][Full Text] [Related]
4. [Metrorrhagia and tamoxifen. Apropos of 22 patients treated for cancer of the breast].
Le Bouëdec G; De Latour M; Feillel V; Dauplat J
J Gynecol Obstet Biol Reprod (Paris); 1990; 19(7):889-94. PubMed ID: 2277172
[TBL] [Abstract][Full Text] [Related]
5. [The use of aminoglutethimide (orimeten) in disseminated breast cancer].
Nadezhdina TM; Vyshinskaia GV; Lichinitser MR; Bassalyk LS; Garin AM
Vopr Onkol; 1987; 33(5):79-82. PubMed ID: 3590672
[TBL] [Abstract][Full Text] [Related]
6. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
Johansen J; Overgaard J; Overgaard M
Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
[TBL] [Abstract][Full Text] [Related]
7. [Anti-oestrogen treatment of metastasising carcinoma of the breast (author's transl)].
Henningsen B; Amberger H
Dtsch Med Wochenschr; 1977 May; 102(19):713-6. PubMed ID: 870301
[TBL] [Abstract][Full Text] [Related]
8. [Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial].
Delozier T; Switsers O; Génot JY; Ollivier JM; Héry M; Namer M; Frenay M; Kerbrat P; Julien JP; Naja A; Janvier M; Macé-Lesec'h J
Bull Cancer; 1997 Jan; 84(1):25-30. PubMed ID: 9180855
[TBL] [Abstract][Full Text] [Related]
9. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
10. [The treatment of metastasizing breast carcinoma using antiestrogens].
Pienkowski T; Palucka-Bartoszewicz A; Pienkowska F; Zborzil J; Schneider J
Wien Med Wochenschr; 1991; 141(13):294, 297-300. PubMed ID: 1926878
[TBL] [Abstract][Full Text] [Related]
11. Anti-oestrogen therapy for breast cancer--a report on 300 patients treated with tamoxifen.
Ward HW; Arthur K; Banks AJ; Bond WH; Brown I; Freeman WE; Holme GM; Jones WG; Newsholme GA; Ostrowski MJ
Clin Oncol; 1978 Mar; 4(1):11-7. PubMed ID: 639375
[No Abstract] [Full Text] [Related]
12. [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
Garcia-Giralt E; Omodei Zorini C; Ferri L; Ayme Y; Carton M; Daban A; Delozier T; Fargeot P; Fumoleau P; Gorins A
Clin Ter; 1994 Aug; 145(8):113-21. PubMed ID: 7955956
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
14. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of advanced breast cancer with tamoxifen (author's transl)].
Alonso Muñóz A; Pérez Manga G; Moreno Esteban B; Muñóz Gómez S; Madrigal Alonso PL; Pérez Modrego S
Med Clin (Barc); 1980 Jul; 75(3):93-7. PubMed ID: 7401744
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
17. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen.
Lahti E; Blanco G; Kauppila A; Apaja-Sarkkinen M; Taskinen PJ; Laatikainen T
Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):660-4. PubMed ID: 8469450
[TBL] [Abstract][Full Text] [Related]
18. [Hormone therapy of metastasizing breast cancer with tamoxifen].
Köhler A; Noss W; Dobberstein N; Stoltmann R; Pohl J
Z Gesamte Inn Med; 1986 Jan; 41(1):6-9. PubMed ID: 3953121
[TBL] [Abstract][Full Text] [Related]
19. [Effect of the estrogen antagonist tamoxifen in the treatment of advanced mastocarcinoma (author's transl)].
Szepesi T; Kärcher KH
Strahlentherapie; 1977 Dec; 153(12):832-6. PubMed ID: 341420
[TBL] [Abstract][Full Text] [Related]
20. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
